Private Capital Group’s Adaptive Biotechnologies ADPT Stock Holding History

Private Capital Group’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1K	Sell	108 -728	-87%	-$6.4K	﹤0.01%	1649
2022 Q1	$12K	Buy	836 +108	+15%	+$1.7K	﹤0.01%	1201
2021 Q4	$20K	Buy	728 +19	+3%	+$582	﹤0.01%	1059
2021 Q3	$24K	Buy	709 +140	+25%	+$5.06K	0.01%	984
2021 Q2	$23K	Sell	569 -46	-7%	-$1.79K	0.01%	1010
2021 Q1	$25K	Buy	615 +570	+1,267%	+$30.9K	0.01%	942
2020 Q4	$3K	Hold	45	–	–	﹤0.01%	1646
2020 Q3	$2K	Sell	45 -2	-4%	-$84	﹤0.01%	1675
2020 Q2	$2K	Buy	+47	New	+$1.71K	﹤0.01%	1661

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $159M AUM 139.66% 1-Year Est. Return

Private Capital Group's ADPT Position: Q2 2022 in Review

Private Capital Group reduced its Adaptive Biotechnologies (ADPT) stake by 87% in Q2 2022, selling an estimated $6.4K and leaving 108 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1649.

Private Capital Group first reported a position in ADPT in Q2 2020 and has held it in 9 quarters since. The position peaked at $25K in Q1 2021. 209 funds tracked by Wall St. Rank hold ADPT as of Q2 2022.

Private Capital Group held 108 shares of Adaptive Biotechnologies worth $1K as of Q2 2022.
Private Capital Group sold 728 Adaptive Biotechnologies shares in Q2 2022, an estimated $6.4K.
Adaptive Biotechnologies made up ﹤0.01% of Private Capital Group's portfolio in Q2 2022, its #1649 holding.
Private Capital Group first reported a position in Adaptive Biotechnologies in Q2 2020 and has held it in 9 quarters since.
Private Capital Group's Adaptive Biotechnologies position peaked at $25K in Q1 2021.
209 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.